HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy.

Trial Profile

HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Gastrointestinal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms HYPAZ
  • Most Recent Events

    • 20 Jul 2015 Planned End Date changed from 1 Sep 2018 to 1 Sep 2015 as per ClinicalTrials.gov record.
    • 20 Jul 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record..
    • 18 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top